Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-05-27 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Investor Presentation Classification · 85% confidence The document is an investor relations activity record from Chengdu Oukang Pharmaceutical Co., Ltd., dated May 28, 2025. It details a specific investor meeting with questions and answers about the company's products, market position, technology, and future growth prospects. The content is a Q&A format focusing on business strategy, product pricing, market competition, and development plans. It does not contain financial statements, earnings highlights, or regulatory certifications. It is not a formal earnings release, annual or interim report, audit report, or any regulatory filing. It is also not a presentation or proxy solicitation. The document fits best as a detailed investor relations activity record, which aligns with the category of Investor Presentation (IP) because it provides detailed information for investors about the company's strategy, market, and outlook, even though it is in Q&A format rather than slides. The document length is under 5,000 characters, but it is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is Investor Presentation (IP).
2025-05-27 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024 Annual General Meeting Resolution Announcement" from Chengdu Oukang Pharmaceutical Co., Ltd. It details the convening, attendance, and voting results of the 2024 annual shareholders meeting held on May 16, 2025. The document includes resolutions passed on various reports and proposals such as the 2024 annual report, board work report, supervisory board report, financial statements, budget, dividend distribution plan, and remuneration plans. It also includes legal opinions confirming the meeting's legality. The content is focused on the official announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or detailed financial statements themselves. The document length is about 4046 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits best under the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2025-05-18 Chinese
投资者关系活动记录表
Investor Presentation Classification · 90% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a specific investor relations event held on May 15, 2025, including questions and answers about the company's operations, production lines, market outlook, and financial impacts such as depreciation and gross margin recovery. The content is a Q&A format from an investor relations meeting rather than a formal earnings release or financial report. The document length is 1913 characters, which is relatively short and focused on investor relations activities rather than comprehensive financial data or official report filings. There is no indication of it being a transcript of a conference call, nor is it an announcement of voting results, capital changes, or legal matters. It is not a formal financial report like an Annual Report (10-K) or Interim Report (IR). The closest fitting category is Investor Presentation (IP) or possibly Call Transcript (CT), but since this is a record of an investor relations activity with Q&A, it aligns best with Investor Presentation (IP) which includes detailed presentations for investors focusing on financials, strategy, and market position. Therefore, the classification is Investor Presentation (IP).
2025-05-18 Chinese
北京德恒（重庆）律师事务所关于成都欧康医药股份有限公司2024年年度股东会的法律意见
Regulatory Filings
2025-05-18 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It specifically mentions that the activity is a "业绩说明会" or "Earnings Explanation Meeting" related to the company's 2024 Annual Report. The content consists of a Q&A session where company executives respond to investor questions about the company's 2024 financial performance, market outlook, product details, and future expectations. This matches the characteristics of a Call Transcript (CT), as it is a detailed transcript of a company event focused on financial results and investor communication. The document length is 4643 characters, which is consistent with a transcript rather than a brief announcement or a full annual report. There is no indication that this is a report itself or a simple announcement of a report publication. Therefore, the best classification is Call Transcript (CT).
2025-04-29 Chinese
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Chengdu Oukang Pharmaceutical Co., Ltd. It details the convening and attendance of the fourth board's ninth meeting, including the approval of the 2025 first quarter report. The document references the actual quarterly report published separately on the Beijing Stock Exchange information disclosure platform (announcement number 2025-042). The text itself does not contain the financial data or the full quarterly report but only the board's approval of it. The document length is short (1064 characters) and serves as an announcement of the board meeting resolution rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board decisions and meeting outcomes related to management activities.
2025-04-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.